Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by OS Therapies
OS Therapies to Present at The Spartan Capital Investor Conference
November 04, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
October 30, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
October 28, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies to Present at the LD Micro Main Event XVII
October 24, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
October 17, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
October 03, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
September 13, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
September 05, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
August 29, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
August 22, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Clarifies CUSIP of Common Stock
August 22, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
August 19, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Announces Full Enrollment in PhIIb Clinical Trial AOST-2121 in Recurred, Resected Osteosarcoma with OST-HER2 (Listeria monocytogenes) for Delay or Prevention of Recurrence
September 26, 2023
From
OS Therapies
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.